nafamostat has been researched along with Neurodegenerative Diseases in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Neurodegenerative Diseases: Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhigulin, AS | 1 |
| Barygin, OI | 1 |
1 other study available for nafamostat and Neurodegenerative Diseases
| Article | Year |
|---|---|
Mechanisms of NMDA receptor inhibition by nafamostat, gabexate and furamidine.
Topics: Animals; Benzamidines; Drug Repositioning; Esters; Gabexate; Guanidines; Hippocampus; Inhibitory Con | 2022 |